November 26, 2018

The Honorable Gus Bilirakis U.S. House of Representatives 2112 Rayburn House Office Building Washington, DC 20515 The Honorable Ben Ray Lujan U.S. House of Representatives 2231 Rayburn House Office Building Washington, DC 20515

Dear Representative Bilirakis and Representative Lujan,

On behalf of the undersigned organizations, representing patients, medical researchers, providers, survivors and their families, thank you for introducing H.R. 6836, the *CLINICAL TREATMENT Act*. As organizations that value patient access to clinical trials, we are pleased to endorse your legislation, which would ensure states cover routine care costs of participation in an approved clinical trial for Medicaid enrollees with life-threatening conditions.

Medicaid insures nearly one-fifth of the US population and is the only major payer that is not required by federal law to cover routine costs associated with participation in clinical trials. This coverage is already assured for Medicare beneficiaries and for patients with private health insurance. Although twelve states require their Medicaid programs to cover these costs, there are still as many as 42.2 million Medicaid patients that are potentially without this needed coverage.

Routine costs include the non-experimental costs of treating a patient who is participating in a clinical trial, such as the cost of physician visits or laboratory tests. These costs are part of standard care and would be incurred regardless of whether a patient participates in a clinical trial. The cost of any investigative device or drug would continue to be covered by the trial sponsor. As such, this coverage would have little to no impact on the overall cost of care to Medicaid programs.

Importantly, clinical trials often provide patients with the best—perhaps only—treatment option for their condition. Without the guarantee of coverage, however, many Medicaid beneficiaries do not have the latest technological and scientific advancements as a treatment option.

Robust clinical trial participation improves the quality of medical research. Medicaid serves many demographics, including ethnic minorities, that are underrepresented in current clinical trial enrollment. Lack of participation in clinical trials from the Medicaid population means these patients are being excluded from potentially life- saving trials and are not reflected in the outcome of the clinical research. Increased access to clinical trial participation for Medicaid enrollees helps ensure medical research results more accurately capture and reflect the populations of this country.

Thank you for your leadership on this issue. We urge others in Congress to support your legislation and are eager to help you advance the *CLINICAL TREATMENT Act*.

Sincerely,

African Services Committee American Association for Cancer Research American Cancer Society Cancer Action Network American Heart Association

American Medical Association

American Society for Radiation Oncology

American Society of Clinical Oncology

The Arizona Clinical Oncology Society

Asian Services Action, Inc.

Association of American Cancer Institutes

Association of Community Cancer Centers

Association of Northern California Oncologists

Association of Pediatric Hematology/Oncology Nurses

The Blue Hat Foundation

Cancer Support Community

CancerCare

Charlene Miers Foundation for Cancer Research

Children's Cause for Cancer Advocacy

Colon Cancer Coalition

Colon Cancer Stars

COLONTOWN, a patient community supported by the PALTOWN DEVELOPMENT FOUNDATION

Colorectal Cancer Alliance

Denali Oncology Group

Dermatology Nurses' Association

Empire State Hematology & Oncology Society

Fight Colorectal Cancer

Florida Society of Clinical Oncology

FORCE: Facing Our Risk of Cancer Empowered

Hawaii Society of Clinical Oncology

Hematology/Oncology Pharmacy Association

Illinois Medical Oncology Society

Indiana Oncology Society

International Myeloma Foundation

Iowa Oncology Society

Kansas Society of Clinical Oncology

Kentucky Association of Medical Oncology

Kiel Colon Cancer Foundation

The Leukemia & Lymphoma Society

Livestrong

Louisiana Oncology Society

Lung Cancer Alliance

Lymphoma Research Foundation

Medical Oncology Society of New Jersey

Michigan Society of Hematology and Oncology

Minnesota Society of Clinical Oncology

Missouri Oncology Society

Montana State Oncology Society

National Brain Tumor Society

National Comprehensive Cancer Network

National Hispanic Medical Association

National Patient Advocate Foundation

Nebraska Oncology Society

Nevada Oncology Society

North Carolina Oncology Association

Northern New England Clinical Oncology Society

NothingPink

Ohio Hematology Oncology Society

Oncology Nursing Society

Ovarian Cancer Research Alliance

Pancreatic Cancer Action Network

Pediatric Palliative Care Coalition

Prevent Cancer Foundation

Research Advocacy Network

Rocky Mountain Oncology Society

Roswell Park Comprehensive Cancer Center

Sarcoma Foundation of America

Society for Immunotherapy of Cancer (SITC)

Society of Utah Medical Oncologists

South Carolina Oncology Society

Tennessee Oncology Practice Society

Texas Society of Clinical Oncology

Triage Cancer

Virginia Association of Hematologists and Oncologists

The Women's Zionist Organization of America

West Virginia Oncology Society

Wisconsin Association of Hematology and Oncology